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ABSTRACT 
 INTRODUCTION 
          Dengue fever is highly prevalent in Tamilnadu and it has caused 
several outbreaks in the recent years .Notable areas involved in the recent 
outbreaks includes Chennai, Madurai and Tirunelveli with significant 
mortality and morbidity. Most patients with dengue fever have liver 
involvement in the form of elevated serum aminotransferases. The elevation 
of enzymes is due to reactive hepatitis as well as direct injury to hepatocytes 
by the virus itself. Patients with hepatitis are more likely to have increased 
risk of bleeding tendencies, renal failure, encephalopathy and acalculous 
cholecystitis.  In addition to thrombocytopenia, deranged liver function 
plays a significant role in bleeding. Hence, evaluation of liver function, 
particularly the aminotransferases, should be a routine in the management of 
dengue fever. 
METHODS     
A total of 60 patients with dengue IG-M  ELISA positive  admitted to 
Institute of Internal Medicine, Rajiv Gandhi Government General Hospital, 
Chennai were included in this study. Patients have their history taken 
according to a questionnaire and subjected to clinical examination and 
investigations like complete blood count, plasma glucose, blood urea, serum 
creatinine, QBC for MP/MF, MSAT for leptospirosis, blood culture, widal 
test, anti-HAV, HBsAg, anti HCV, chest X- ray, USG abdomen and liver 
function tests. 
RESULTS 
        Out of 60 patients, 36 patients had elevated liver enzymes.  Those 
patients were at risk of severe bleeding, shock, ARDS, hepatitis and other 
complications.  There was a significant difference (p value<0.05) between 
serum aminotransferase values and bleeding, shock, ARDS and hepatitis. 
There was a negative correlation between liver enzymes and platelets.  Of 
the liver enzymes, AST levels were higher compared to ALT levels (mean 
AST-259.45& mean ALT- 199.75). 
CONCLUSION 
Hepatic involvement is common in dengue fever. It is characterised 
by elevated liver enzymes, AST more than ALT levels. Elevated liver 
enzymes were associated with complications like bleeding, shock and organ 
impairment. In addition to thrombocytopenia, hepatic involvement plays a 
significant role in bleeding.  Elevated liver enzymes have got prognostic 
value in this study.  Hence, liver enzymes are mandatory in dengue fever to 
look for complications and it is of prognostic value.  Those patients with 
elevated liver enzymes should be monitored carefully than those with 
normal liver enzymes. 
Key Words:  
Dengue Fever, Serum Aminotransferases,  Thrombocytopaenia, Bleeding. 
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INTRODUCTION 
Dengue fever (DF) is usually a self limited mosquito borne viral 
disease.It is caused by one among the 4 subtypes of dengue viruses.  
Characteristic features are fever and minimal constitutional symptoms to 
shock and bleeding tendencies or dengue shock syndrome / dengue 
hemorrhagic fever (DSS/DHF).  The worldwide spread of dengue  has 
increased dramatically nowadays to be endemic in 112 countries of South 
East Asia, Africa, South and North America and the Mediterranean regions.  
In tropical and subtropical regions nearly about 2.5 billion people are at risk 
for dengue fever.  
Each year around 45-105 million reported cases of dengue, 550,000 
reported cases of dengue hemorrhagic fever & atleast about 13,000 deaths 
because of dengue occurs throughout the world.  90% of dengue mortality 
was seen in children <14 years.  Dengue fever and dengue hemorrhagic 
fever is currently endemic in countries like Bangladesh, Myanmar, Sri 
Lanka, India, Thailand and other South East Asian countries.  
  
Dengue fever is highly prevalent in Tamilnadu and it has caused 
several outbreaks in the recent years.  Notable areas involved in the recent 
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outbreaks include Chennai, Tirunelveli and Madurai with significant 
morbidity and mortality.   
  
The spectrum of dengue fever includes: 
 Asymptomatic 
 Acute Fever 
 Classical dengue  
 ‘Dengue hemorrhagic fever’ including the ‘Dengue shock 
syndrome’. 
‘Classical Dengue’ fever evolves through three phases: 
 Febrile phase 
 Critical phase 
 Recovery phase        
Though dengue is a self limited viral disease, it leads to life 
threatening complications in significant number of patients especially 
during the critical phase of the illness.             
‘Severe dengue’ is classified by the following characteristics: 
 Plasma leakage causing shock, the dengue shock & free fluid 
accumulation along with respiratory suffocation or without it. 
 Massive bleeding 
 Severe organ damage 
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The standard of care in the management of dengue fever involves 
close monitoring of vital parameters, platelet count and hematocrit.  It has 
been shown that most patients with dengue fever have liver involvement in 
the form of elevated serum aminotransferases.  The elevation of enzymes is 
due to reactive hepatitis as well as direct injury to hepatocytes by the virus 
itself. Patients with hepatitis are more likely to have increased risk of 
bleeding tendencies, renal failure, encephalopathy and acalculous 
cholecystitis.  In addition to thrombocytopenia, deranged liver function 
plays a significant role in bleeding. Hence, evaluation of liver function, 
particularly the aminotransferases, should be a routine in the management of 
patients with dengue fever.   
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVE      
 To measure serum aminotransferase levels in patient with dengue 
fever                                            
SECONDARY OBJECTIVE   
 To correlate serum aminotransferase levels with the severity of 
dengue fever 
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REVIEW OF LITERATURE 
 The term “Dengue” was introduced from the West Indies into the 
English medical literature during the year 1827 – 28, Caribbean epidemic of 
an exanthema with arthralgia.  It is a Spanish homonym for the Swahili “Ki 
denga Pepo” which is a sudden cramp like seizure caused due to an evil 
spirit.  The usage of the term “Break bone fever” for the dengue was known 
since 1780 in Philadelphia. 
 In 1897, numerous shock cases and deaths were reported due to 
dengue epidemic in queensland,Australia. Similar incident was noted during 
the massive dengue epidemic of 1928 which occurred in greek where nearly 
1250 persons died because of dengue.  The greek epidemic was due to  the   
poor  living conditions among refugees  from Turkey following  the  1922 
Greco-Turkish war .  The dengue viruses were adapted to laboratory 
animals for the first time during 1940’s (type land 2) and 1950’s (type 3 and 
4)
6,7
. 
INCIDENCE 
Global burden 
 “Dengue Hemorrhagic fever (DHF)” is defined by 4 major features 
viz. 
 High grade Fever 
 Bleeding phenomena  
11 
 
 Liver enlargement 
  Signs of circulatory failure 
Dengue outbreaks were noticed over the 19
th
 & early part of 20
th
 
centuries. Notable areas include the “Southern part of Europe, America, 
Northern part of Africa, Asia and Australia, the eastern part of 
Mediterranean and on numerous islands in the Arabian Ocean & the  
Caribbean”
1,2
.    
Dengue in the South-East Regions of Asia & Western part of Pacific 
Regions 
 ‘Dengue hemorrhagic fever’ was first noticed in 1953 in Philippines.  
It was linked to dengue viruses etiologically because of dengue subtypes 
two, three and four recovered from patients in 1956.Numerous subtypes of 
dengue viruses were discovered from patients in Thailand two years later in 
an epidemic. After thirty years, DHF/DSS was found in some parts of 
“china, Malaysia, Cambodia, Malaysia, the Republic of Lao people and 
several pacific island groups”
1,2
.   
 “ Dengue haemorrhagic fever/Dengue shock syndrome” progressively 
spreading as an major public  health concern, from its prime location  to 
small towns & cities in epidemic areas during 1960s and 1970s.  It followed 
a seasonal and also a periodical outbreak patterns, with epidemics occurring 
regularly at two or three years gap.  In 1980s, “DHF/DSS” affected even the 
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smaller villages in the endemic countries.  Exceptionally larger outbreaks 
happened in Vietnam and Thailand in 1988.The amount of people  acquiring 
& dying due to ‘DHF/DSS’ noticed in every parts of south east Asia & 
western pacific was 23,793 and 1,946,965 respectively during 1980s.  New 
introductions of DHF/DSS were reported in India (1988), New Caledonia 
(1988), China (1985), Srilanka (1989), Tahiti (1989), and Maldives (1985)  
epidemiologically.  The reports in Sri Lanka and India are interesting 
particularly because ‘virological surveillance in these areas reported the 
local transmission of four dengue serotypes and DF cases, but not due 
to‘DHF/DSS’ previous to the above mentioned massive outbreaks’
1,2
.   
 The sequence has been the same in each of these countries where 
DHF has becoming endemic.  Frequent  dengue virus transmission, initially 
due to  single cases of ‘Dengue haemorrhagic fever’ and then succeeded by 
DHF outbreaks were increasing gradually until the  DHF cases were  seen 
almost  all the year, with severe outbreaks taking place at an interval of  3 to 
5 years.   All 4 dengue virus serotypes are seen in these two regions, and 
because of increasing international travelers, new virus serotypes and strains 
were rapidly introduced into the susceptible populations.  ‘Dengue fever and 
Dengue haemorrhagic fever’, primarily an disease affecting young children 
because of  the largest proportion  of susceptible individuals within the 
group of  population at risk for disease.  Interestingly, among the travelers, 
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DF & DHF is now occasionally found. Dengue haemorrhagic feve is 
causing an severe public health related problems in many regions in the 
South-East part of Asian countries and also in some Pacific regions.  ‘One 
of the 10 major reasons for hospitalization and mortality in younger age 
groups in about 8 countries in Asia is due to dengue’
1,2
.   
 
 
Epidemics of the dengue illness in India
8
  
 Dengue fever is endemic in most parts of our country in exception to 
the Himalayan and other hilly regions where conditions are not suitable for 
the vector to propogate.   
  In some countries there is an periodical pattern of virus spread 
especially during the winter season “Temperature & Rain” are the two most 
significant factors for dengue virus spread, since decreased temperatures 
will affect the survival of adult mosquitoes and thereby affecting the 
transmission rates.  In addition to, rain & temperature also alter the 
mosquito pattern of reproduction and also feeding, and thereby affecting  
the population density  of  vectors.   
Though DHF may affect persons of all age groups, most of the cases 
are seen in children of < 14 years of age in endemic areas. The local trend in 
Bangkok, Thailand since 1964 has progressively approaching the lesser 
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attack ratio, with the modal age for in hospital child being six to seven years 
all over the Thailand.   A modest increase of affected girls compared to boys 
in some areas whereas other regions have almost showed an even gender 
distribution in surveillance data.   
DENGUE VIRUSES 
 Dengue fever is due to dengue virus belonging to the genus 
“flavivirus” and the family “flaviviridae”.  It is composed of a single 
standard RNA virus of four distinct serotypes ‘(DEN I to IV)’.  Dengue 
virus is 50 mm in diameter and it is spherical in shape.  It contains “multiple 
copies of the three structural proteins, a copy of a positive sense, single 
stranded RNA genome and a host derived membrane bilayer”.  It also 
contains seven nonstructural proteins (NS).  The biologically important viral 
properties are situated in the E protein.  Some of the ‘nonstructural proteins 
are important in the viral replication’
9
.  Individuals infected with one 
dengue virus subtype are immune to that subtype only.  Theoretically, all 
four dengue subtypes can infect the individuals. Initially DEN-2 was the 
predominant serotype but now DEN-3 has becoming more common
10
. 
Transmission 
 It is spread to human beings mainly through the bites of infected 
‘Aedes mosquitoes’, mostly “Aedes aegypti”.  Other species responsible for 
transmission to humans are “Aedes albopictus, Aedes polynesiensis and 
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several species of the Aedes scrotellaris complex”. The female mosquitoes  
are incorporated with dengue virus  after  they suck bloody meal  from the 
diseased person at the time of fever (viraemic phase).The infected  
mosquitoes then transmit the infection by biting as well as injecting  
infected salivary fluid in to other person after an extrinsic incubation period 
of about eight to ten days. A single female mosquito which is infected is 
adequate for vertical transmission of the virus to following generation, 
which is responsible for the virus maintenance and not for the epidemiology 
aspect  of the disease. Rarely a mother to child transmission was also 
reported.   
 Transmission of dengue virus occurs in variable areas, including 
tropical and subtropical areas at different altitudes.  The Aedes rests mainly 
in indoors, in bedrooms and in living rooms and also in small water 
collections like coconut shells and flowerpots
11,12
.  This increases man to 
vector contact and thereby reducing the mosquitoes contact with insecticidal 
agents sprayed outsides and thereby hindering the control of the vectors
13
.  
Mosquito eggs are able to survive for longer duration of time.  In endemic 
areas, high mosquito densities are due to the improper garbage disposal and 
inadequate waste water drainage system. There is a ‘significant 
improvement in the larval productions of the mosquito during rainy season 
16 
 
and that is the reason for outbreaks of dengue occurring during rainy 
season’.   
 
Pathogenesis 
  The average incubation period lasts for about 3 to 8 days (range of 
4to 15 days) after the infected mosquitoes bites the human beings. 
Depending on the characteristics of the viruses, the diseased individuals 
may or may not be able to experience symptoms.’  The incubation period is 
immediately followed by viremia, characterized by sudden occurence of 
fever and systemic  symptoms seen for about  5  to 8 days (range of 2 to 13 
days)’. 
  Replication of dengue virus occurs inside the cellular matter of the 
macrophages, B cells & monocytes.  In addition,” mast cells
14
, dendritic 
cells &endothelial cells” are also infected with dengue virus.  It may also 
infect “liver, spleen, peripheral blood WBCs, lymph nodes, thymus, kidney, 
cardiac, lungs, stomach, and possibly the human brain”, which suggest 
disruption of blood brain barrier
15
.   
  The viremic phase is followed by either dengue and dengue 
hemorrhagic fever.  After that the patient will either recover from the illness 
or they may advances to the more severe leakage syndrome, the Dengue 
shock syndrome.   The dengue infections severity are correlated with the 
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presence of peak plasma viremia and circulating levels of NS1 protein
16
.  
There is an increased expression of cytokines mainly ‘Tumour necrosis 
factor-α and Interferon- α’
17,18
, and  also other chemical substances when the 
number of  infected cells are more. These cytokines in turn leads to the over 
expression of another dendritic cells either infected or non-infected with 
viruses.  The expression of numerous cytokines and other chemical 
mediators are important for the “excessive plasma leakage, decreased 
effective circulating volume, increased vascular permeability, coagulation 
abnormalities and shock”.  Additionally, it is found that an supportive 
evidence for apoptosis of endothelial cells leading to disintegration of the 
endothelial cell barrier and thereby causing the generalized vascular leak 
syndrome
19
.   
 In about 2 to 4% of individuals, there was a more serious infection, 
when a person was infected with a different serotype for a second time.  The 
reason for second time dengue infection causing an serious  illness and why 
only small amount of the  patients are severely  diseased still  remains 
mysterious.   
 Commonly occurring gross pathologic findings like “petechial 
hemorrhages and purpurae, serous  effusions, & also  pulmonary 
congestion”. Small vessel vasculitis is seen in visceral and soft tissues on 
18 
 
microscopy and there were some amount of “focal middle zone liver 
necrosis,gastric mucosal bleeding & subendocardial left ventricle bleeding”.  
 
 
 The remaining antibodies synthesized early in the initial infection are 
not able to antogonise an another infection with a different serotype. The 
second time infection results in severe disease due to the influence of 
enhancing antibodies.  This phenomenon is called as “Antibody –dependent 
enhancement”
20
.   
CLINICAL FEATURES 
 Dengue fever has got a numerous spectrum of clinical features. 
Mostly with unexplained cause and outcome.  It is mostly a self relieving 
less severe disease but a small population of dengue fever progresses to 
severe disease due to plasma leakage with or without hemorrhage.   
 Symptomatic dengue infections were classified in to three groups
21,22
 
1. Undifferentiated fever 
2. Dengue Fever (DF) 
3. Dengue hemorrhagic fever (DHF) – four grades.  Grade III and IV 
Dengue Hemorrhagic Fever (DHF) are called as Dengue Shock 
Syndrome(DSS). 
Probable Dengue 
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 Live in/travel to dengue occurring area 
 “Fever plus any two of the following features: 
 Nausea, vomiting 
 Exanthematous rash 
 Muscle aches & pains 
  Positive for tourniquet procedure  
 Reduced leucocyte count 
 Any of the warning signs” 
“Warning signs of dengue are: 
 Epigastric pain or tenderness 
 Prolonged vomiting 
 Clinically accumulation of fluid 
 Mucosal haemorrhages 
 Slowness, restlessness 
 Hepatic  enlargement greater than 2 cm 
 Increased  HCT concurrent with rapid fall  in thrombocytes 
count”. 
“Severe Dengue Criteria
21,22 
1. Severe  leakage of plasma  causing 
a. Shock (DSS) 
b. Respiratory suffocation 
2. Massive bleeding 
20 
 
3. Severe damage to internal organs 
a. Liver : AST and ALT more than 1000 
b. CNS : altered sensorium 
c. cardiac & other internal  organs” 
21 
 
 
 
 
DENGUE -  CLASSIFICATION OF CASES & LEVELS IN THE 
SEVERITY OF ILLNESS 
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DENGUE FEVER  - COURSE OF ILLNESS 
 
 
“3 phases of Dengue Fever: 
 Febrile phase 
 Critical phase 
 Recovery phase”        
Febrile Phase 
 Lasts for 3 – 8 days 
 Clinically it resembles like any other febrile diseases 
Characterized by body ache, headache, arthralgia, sore throat, 
etc., 
 Clinical presentations are indistinguishable in between severe 
and mild dengue. 
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 Minimal bleeding manifestations may be seen. 
 Earliest abnormality is a ‘progressive reduction in total white  
blood cell count, which may alert the treating doctor to  suspect 
a high probability of dengue’.   
Critical phase 
 Increase in capillary permeability as evidenced by increasing 
haematocrit levels at the time of defervescence. 
 Significant plasma leakage lasts for 24 – 48 hours 
 Before plasma leakage, there is a progressive leucopenia 
followed by rapid decrease in thrombocytes. 
 Shock occurs in this phase which is preceded by warning signs. 
 Progressive organ impairment, metabolic acidosis and DIC 
occurs because of prolonged shock. 
 Total wbc  count may rise in patients with massive bleeding. 
 Severe hepatic involvement, meningoencephalitis, myocarditis 
and profuse bleeding may occur even in the absence of 
obvious  leakage  of plasma and shock. 
Recovery phase 
 Following 24 – 48 hours of critical phase, there will be a gradual 
absorption of extravascular compartment fluid.  General condition of the 
patient and hemodynamic status improves.  Bradycardia and other ECG 
24 
 
changes are common.  WBC returns to normal after that platelet count 
becomes normal.  Excessive fluid management in this phase is associated 
with pulmonary odema or congestive cardiac failure. 
Hemodynamic Assessment 
Parameters 
Stable 
circulation 
Compensated 
shock 
Hypotensive shock 
Hypotensive 
shock 
Clear and 
lucid 
‘Clear and 
lucid’ (shock is 
missed if we 
don’t touch the 
patient) 
Altered mental state(restless / 
combative) 
Capillary 
refill time 
Normal 
(<2 sec) 
Increased (>2s) Prolonged (mottled skin) 
Extremities 
Warm & 
pink 
Peripheries – 
cold 
Cold & clammy 
Peripheral 
pulse volume 
Normal 
Weak  and 
thread 
Feeble / absent 
Blood 
pressure 
Normal 
Normal systolic 
pressure but  
increasing 
diastolic 
pressure, 
narrowed  pulse 
pressure, 
postural 
hyotension 
Narrowed pulse pressure / 
hypotension / BP not 
recordable 
Respiratory 
Rate 
Normal Tachypnoeic 
Metabolic acidosis/ 
Kussmaul’s breathing 
Heart rate Normal Increased 
Severe tachycardia along 
with bradycardia in late 
shock. 
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CRITERIA  FOR ADMISSION 
 
Warning Signs Any one of the warning signs 
Signs &symptoms 
linked to 
hypotension 
Dehydrated patient, not able to swallow oral 
fluids , giddiness , postural hypotension, 
profuse perspiration, dropouts, hypotension 
and  cold extremities. 
Bleeding 
Spontaneous bleeding irrespective of platelet 
count. 
Organ Impairment Renal/ Hepatic/ Neurologic/ Cardiac. 
Investigations 
Increasing hematocrit, pleural effusion, 
ascites/ asymptomatic gall bladder 
thickening. 
Co-existing 
conditions 
Pregnancy, comorbities like Diabetes , 
Hypertension, CAD, overweight or obesity, 
infancy \ geriatric age. 
Social 
circumstances 
 single,  far from health services, without 
reliable modes of transport. 
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Management
23 
• Management of febrile phase 
• Management of the DHF/DSS  
Management of febrile phase 
• Rest, plenty of oral fluids 
• Control of fever: Tepid sponging, Paracetamol 15mg/kg per day in 4 
divided doses every 6hrs. 
• Diet support: Soft and bland healthy diet, plenty of fruit juices and 
electrolyte solutions. Drinking water alone is insufficient.  
• Supportive measures: Domperidone in three divided doses with a 
total dose of one mg/ kg per day. H2 blockers in case of GI bleed. 
Antibiotics are unnecessary and it will even lead on to complications. 
Steroids are controversial and maybe harmful. 
• IV Fluids : In doubtful cases fluids may be given IV. Response to be 
monitored by serial packed cell volume, blood pressure 
measurements & urine output. As soon as dehydration is corrected 
fluids must be discontinued as early as possible. 
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Home care 
After discharge advice the patient about the warnings signs & 
symptoms of dengue shock syndrome, and advice them to visit nearby 
hospital immediately if one of the following features occur: 
 Recurrence of fever 
 Bleeding  
 Refusal of oral feeds 
 Intense thirst 
 Drowsy or sleepy 
 Severe vomiting 
 Unbearable abdominal pain 
 Altered mental state 
 Cold peripheries 
 Decreased urine output 
Follow up 
Daily till the patient is afebrile for two consecutive days. 
Monitoring in follow up 
History: Bleeding manifestation, urine output, pain abdomen, appetite, 
vomiting 
Physical examination: Pulse, BP, Respiratory rate 
28 
 
• Lab investigations: CBC – WBC count <5000 with predominant 
lymphocytes and presence of  atypical cells. Platelet count < one lac. 
Rising hematcrit.  LFT – in case a patient has altered sensorium. 
MANAGEMENT OF DHF/DSS 
GENERAL MEASURES INCLUDES: 
 In case of shock or impending shock, give oxygen through 
face mask or through nasal cannula.  
 Frequent monitoring of vital signs 
 In case of bleeding, take appropriate steps to control 
bleeding. 
 If necessary sedatives can be used but care should be taken 
not to use long acting one. 
 Blind invasive procedures should be avoided. 
 Proper nursing care. 
MONITORING PARAMETERS: 
 Vitals should be assessed every  half   to one hour till                   
patient becomes stable and then every one to two hours 
afterwards 
 Amount of urine. 
 Serum sodium, potassium and arterial blood gases should 
be taken six to twelfth hourly. 
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 Input and output chart. 
 Haematocrit and platelet count should be checked every four to 
six hours till the patient becomes stable 
 Weight chart 
 Liver function parameters. 
INVESTIGATIONS:           
 Platelet count and haematocrit. 
 Plasma glucose 
 Blood grouping and cross matching 
 Serum electrolytes 
 Arterial blood gas 
 Liver function parameters 
 Renal function test 
 Coagulation profile 
FLUID MANAGEMENT: 
IV fluid type: Isotonic salt solution (Ringer’s lactate or normal saline)    
Fluid rate:  minimal amount needed to effectively maintain the circulatory 
volume since excess of fluids will cause fluid leakage in to pleural and 
peritoneal spaces. 
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Initial fluid rate: 
 Dengue shock syndrome grade 3- 10ml/kg/hr for one to 
two hours. 
 Grade 4 -20ml/kg/hr or free flow iv bolus till the blood 
pressure becomes normal and then titrate the rate to 
10ml/kg/hr for about one to two hrs. 
 No shock – we should have normal maintenance of fluids. 
BLOOD AND PLATELET TRANSFUSION: 
1. INDICATIONS FOR BLOOD TRANSFUSION 
 Significant blood loss > 10%  
 Hemolytic picture 
 occult internal haemorrhages 
 DOSE: fresh whole blood – 10ml/kg/dose,                   
packed cells- 5ml/kg/dose. 
2. INDICATIONS FOR  TRANSFUSION OF PLATELETS 
 profound bleeding with reduced platelet count 
 Platelets <10,000/mm
3
 
About 0.5% of DHF cases require transfusion of platelets and that too 
the platelets usually return to normal within 7 to 10 days. 
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Intravenous fluid infusion algorithm in DHF
22 
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Algorithm for management of dengue haemorrhagic fever
24 
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Algorithm for the management of DSS
25 
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Treatment of complications 
1. Electrolyte imbalance 
a. Hypocalcemia – correction can be done with 10% Calcium 
gluconate 1 ml/kg per dose slow IV sixth hourly. 
b. Hyponatremia – corrections can be done with normal saline or 
hypertronic saline. 
2. Fluid overload – Common causes of fluid overload should be 
avoided, includes:  
a. Excessive usage of hypotonic solutions. 
b. No reduction in the IV fluid rate even after initial resuscitation. 
c. Aggressive IV fluids infusion early in the febrile period.  
d. Fluid replacement for blood loss in cases of occult bleeding.  
e. Liberal fluid removal with the help of colloids or dialysis. 
      3. Massive pleural effusions and ascites 
                  a. close monitoring of IV fluids 
                   b. small doses of frusemide can be tried.  Avoid using insertion    
of intercoastal tubes& tracheal intubation. 
      4. Consumption coagulopathy 
                   Heparin and cryoprecipitate at the dosage of 1.5 units per 5 kg 
body weight, which is succeeded by platelets transfusion at the dosage of 
4units/m
2
 or 10-20ml/kg within 1 hr and fresh frozen plasma at the dosage 
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of 10 -20ml/kg careful clinical assessment and periodic coagulation profile, 
are essential. 
DISCHARGE CRITERIA: 
 Afebrile for atleast 24 hrs without the usuage of 
antipyretics 
  Stable vital parameters for a minimum period of 3 days 
after recovered from shock 
 No internal or external bleeding evidences 
 Adequate urine output 
 Platelets >100,000/mm
3
 
 Normal haematocrit values 
 No evidence of ascites/respiratory distress 
 IV fluid should be discontinued with stable vital signs and with 
haematocrit levels falls to 40% approximately.  Adequate urine flow 
suggests effective circulation.  Extravasated fluids will reabsorb 48 hrs after 
recovering from shock and therefore if more fluid is given during this time, 
hypervolemia, pulmonary oedema and heart failure will occur.  Importantly 
a reduction in packed cell volumes occurring in the last stage should never 
be assumed due to occult haemorrhage.  The resumption of the appetite is 
considered as a very good recovery sign in diseased individual. 
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Prevention & Control 
 Nowadays, no particular drug and vaccine against dengue virus is 
present.  Control is largely dependent up on the control of vector.   
I. Personal protection:  Protective clothes, repellents, insecticide coated 
mosquito nets/curtains. 
II. Environmental factors: good supply of drinking water, roofing of 
above head tanks and also the underground drainage system. 
III. Biological control: with the help of “Gambria affinis and Peorilia 
reticulate”, larvivorous fish. 
IV. Chemical control:  using ‘1% temephos granules and space sprayers 
like malathion, pirimiphos’.  Insect growth regulators can also be 
tried. 
Vaccines 
 Dengue vaccine trial using an quadrivalent live attenuated vaccine 
was conducted in Thailand.  In that trial, after completing the 3
rd
 dose 90% 
of individuals were seroconverted.  It sympathesises that the vaccine has got 
moderate and at the same time improved reaction capacity with higher 
seroconversion rates against 4 serotypes of dengue.  After the two doses of 
vaccine was administered in young children, it produces about 80 to 91% of 
seroconversion rate to all the four dengue subjects.  The vaccine introduced 
by the ‘Walter Reed Army Institute of Research in America’ also got similar 
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seroconversion  in adults.  The molecular mechanism of attenuation by the 
two vaccines is not clearly known.  It is therefore assumed that interference 
with replication and also interference with immune stimulation is 
responsible for the imbalanced immune responses and thereby causing 
incomplete protection and enhanced disease severity.   
Prognosis
3,4,5 
 If initial recognition & monitoring was not done properly, there was a 
significant morbidity and mortality.  The mortality of DHF/DSS was about 
45 to 55% if left untreated.  Early disease recognition, close monitoring and 
adequate fluid management alone have reduced the mortality to about 2%.  
When shock is noticed with the help of pulse pressure starting to drop down 
and immediately  IV fluids are infused, the outcome is usually very good.  
Recovery was also rapid and almost all of the patients recovered within one 
to two days without having much complications.   The outcome is poor 
when the patient developed cold peripheries.  Many of the mortality from 
DHF/DSS are due to excessive bleeding, refractory shock, excessive fluid 
management and fulminent hepatic failure.        
Unusual manifestations 
 Hepatitis 
 Glomerulonephritis 
 Encephalitis 
 Myocardial dysfunction 
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Dengue Fever - Differential Diagnosis  
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Dengue Fever - Differential Diagnosis (Contd..) 
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LIVER INVOLVEMENT IN DENGUE FEVER 
 
Atypical forms of dengue infection are numerous.  Notable one is 
liver dysfunction.  Liver injury is due to either direct injury to hepataocytes 
by virus itself or indirectly due to an immune mediated damage to 
hepatocytes.  Even though liver is usually not affected by virus, numerous 
pathological changes like “steatosis, centrilobular cell necrosis & monocyte 
implantation in the portal tract” is noticed.     
 
 Chen HC et al
51
 in 2004 reported that there was a “significant 
correlation between T lymphocyte activation and liver dysfunction in 
immunocompetent mice”.  In one study, about three tenths of all patients are 
presented with liver dysfunction.  Liver dysfunction is considerably higher 
in Asian populations ranging from 30 – 90%.  The rate of liver dysfunction 
in patients with shock is higher than the patient without shock.   
 Recently Pancharoen et al
34
 reported that ‘average of SGOT and 
SGPT enzyme levels were significantly raised in patients of severe dengue 
infections’.    
 Hepatic involvement is not that much uncommon in dengue fever as 
seen in literature since 1975.  Most common abnormality in liver function 
test is increased transaminases and they are involved in metabolism of 
amino acids.  AST is found to be higher than that of ALT levels.  In more 
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than 90% of patients with dengue fever, the virus itself initiates some 
inflammatory responses which causes hepatic parenchymal damage and 
release of transaminases in to systemic circulation. 
 
Table I : Primary outcomes according to  hepatitis severity 
       within 2 categories of diagnosis 
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Table II : Complications in 2  hepatitis groups 
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Figure I : Kaplan-Meir curve for  survival over the period of time in 2 
groups of  hepatitis patients 
 
 
 ‘Prakasah et al
52
 postulated that the fatal hepatitis will cause an 
important cofactor for case fatality in dengue patients’.  They also found 
that patients with severe hepatitis are likely to be more prone for renal 
failure, encephalopathy, severe bleeding and acalculous cholecystitis.   
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 Kho CH et al
30
 came with the report that those patients with higher 
levels of AST/ALT levels are likely to have severe bleeding tendencies.   
 Nguyen et al
31
 found that those patients with gastrointestinal 
hemorrhage are having elevated AST and ALT levels.  They also found that 
in addition to thrombocytopenia, deranged hepatic function may have a role 
in bleeding. 
 Acalculous cholecystitis and encephalopathy are significantly higher 
in individuals with fatal hepatitis. 
 “Prakash et al
52
 found that that when liver function tests are damaged,  
dengue fever should be ruled out apart from routine hepatotrophic virus”.   
 Arun Sedhain et al
45
 study also confirmed that levels of AST and 
ALT were significantly higher in Dengue Hemorrhagic Fever (DHF) 
patients than Dengue Fever (DF) and that too AST levels were greater than 
ALT levels, as opposed to viral hepatitis. 
Table : 3 Laboratory parameters of DF and DHF patients. 
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They also found out that liver involvement is more severe in cases of 
DEN-3 and DEN-4 viruses.  Many studies used an immunohisto chemical 
method to detect the presence of dengue antigens in liver specimens.  They 
predominantly used antibodies directing against dengue E protein and 
recently antibody against dengue NS3 protein is also used.  Majority of the 
studies detected the presence of dengue antigen in hepatocytes.  
 Table : 4 Ultrasonologic manifestations of DF and DHF patients. 
 
Table 5 : Comparison of certain characteristics in dengue hemorrhagic 
fever and dengue fever 
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Table 6 : Clinical characteristics and lab parameters in the 
study subjects 
 
 Presence of vomiting from day one may indicate the possibility of 
hepatic dysfunction.   
 PT and aPTT derangements are mild with aPH being more affected 
than PT. 
 AST and ALT values were significantly elevated in individuals with 
any of the following features: 
1. Patients with dengue hemorrhagic fever or secondary dengue. 
2. Thrombocytopaenia or an increased haematocrit. 
3. Nausea / Vomiting 
4. Hepatomegaly 
5. Bleeding tendencies 
47 
 
“Kho et al reported that SGOT begins to raise from 3
rd
 day of illness reaches 
a peak on 8
th
 to 9
th
 day of illness & normalizes at around third week”. 
PATHOGENESIS OF HEPATIC DYSFUCTION
29,41 
 Histological changes in liver because of dengue include: 
1. Hepatocellular necrosis 
2. Councilman bodies 
3. Kupffer cell hyperplasia and destruction 
4. Micro vesicular steatosis 
5. Cellular infiltrates at the portal tract 
In dengue, hepatocellular necrosis most commonly involves the mid 
zonal area and at times centrilobular area.  This is because mid zonal area 
hepatocytes are more prone to anoxic injury or immunological injury or 
sometimes the virus may preferentially attack cells in this zone. 
Dengue viral RNA can be detected in mid zonal hepatocytes using an 
PCR method of archives paraffin embedded autopsy tissues.  Pathological 
changes seen in liver in dengue liver is similar to that of yellow fever
26,27,28
.  
But hepatocellular necrosis is more severe and extensive in yellow fever.  
Dengue viral antigens are seen mainly as focal cytoplasmic foci and large 
perinuclear inclusions whereas yellow fever antigenic particles were 
uniformly distributed throughout the cytoplasm. 
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Dengue infection of ‘HePG2 cells’ causes expression of only a small 
amount of  infections particles and it causes a slight rise in the amount of 
antigen enclosing cells over the period of time.  But as against the dengue 
fever, yellow fever viruses multiplied in high amount of titres and it infects 
almost every susceptible cells in the liver.   
‘Dengue virus affected cells rapidly died as a result of apoptosis 
whereas yellow fever virus infected cells die lately’.  Dengue fever virus can 
replicate both in kupffer cells and in hepatocytes though dengue virus enters 
the kupffer cells.  Replication of virus particles in the kupffer cells are not 
effective.  This is because viral antigenic particles enter the kupffer cells by 
the method of phagocytosis which usually causes viral degradation.   
In order to mention the occurrence of severe disease, ‘immune 
enhancement and virus virulence hypothesis’ have been developed.  Those 
individuals who are exposing to secondary dengue infection with another 
dengue virus serotype are more likely to have increased DFS/DHF.  This 
observation can be explained by the antibody dependent enhancement 
therapy.   
Already existing non neutralizing antibodies will form complexes 
within the virus particles and it will increase its uptake & replication in 
macrophage system of our body during secondary dengue virus infections.   
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During dengue infection, ‘B cells, mast cells, monocytes and T.cells’ 
produces larger amounts of cytokines.  During first three days of illness, 
‘TNF-α, IL-2,IL-6, IFN-α’ are highest in the serum whereas’ IL-10, IL-5, 
IL-4’ appears later.  IFN-α protects against severe dengue infections 
whereas IL-6, IL-5 increases the occurrence of DHF/DSS. 
“Gagnon et al (1999) have reported that CD4+ cytotoxic T cells are 
responsible for liver destruction in dengue fever involving a mechanism 
which involves bystander lyses”.  ‘CD4+ mediated cytotoxicity’ occurs via 
two pathways.   
1. Activated CD4+ cytotoxic T cells releases perborin and granymes. 
2. ‘Fas on the target cell ineracts with Fas ligand on the T cells’.        
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MATERIAL AND METHODS 
STUDY CENTRE 
Institute of Internal Medicine, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai. 
DURATION OF THE STUDY 
6 months 
STUDY DESIGN 
Cross sectional study 
SAMPLE SIZE 
60 patients 
DATA COLLECTION AND METHODS 
Patients have their history taken according to a questionnaire and 
subjected to clinical examination and patients were subjected to the 
investigations of complete blood count, ,plasma glucose, blood urea, serum 
creatinine, QBC for MP/MF, MSAT for leptospirosis, blood culture, widal, 
anti-HAV, HBsAg, anti HCV, Chest X-ray, USG abdomen and liver 
function tets.   
PRODUCT / PROCEDURE / INVESTIGATION DETAILS 
Serum aminotransferase levels 
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INCLUSION CRITERIA 
Patients aged >18 years and dengue IgM positive. 
EXCLUSION CRITERIA  
Chronic liver disease, viral hepatitis (Hepatitis A,B and C), Malaria, 
Leptospirosis, Typhoid and history of alcohol abuse. 
STATISTICAL METHODS  
The statistical analysis is done based on paired chi-square and p-value 
is calculated using paired t-statistic.  
SPONSORSHIP 
 No  
CONFLICT OF INTEREST 
 None  
 
 
 
 
 
 
 
 
 
52 
 
OBSERVATIONS AND RESULTS 
 
TABLE 1 : SEX DISTRIBUTION OF AST CATEGORY 
 
 
AST category 
Total 
High Normal 
Male 22 10 32 
Female 14 14 28 
Total 36 24 60 
 
Out of 60 patients studied, males were 32 and females were 28.  Chi 
square test was applied to test the significance between the AST levels and 
sex distribution.  There was no significant difference (p = 0.139) found 
between the variations in the AST levels and sex distribution.  This implies 
that AST levels does not depends upon the sex distribution.   
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SEX DISTRIBUTION OF AST CATEGORY 
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TABLE 2 : AGE DISTRIBUTION OF PATIENTS 
 
 
Age Range No.of Patients Percentage 
18 – 25 12 20% 
26 – 30 8 13% 
31 – 35 5 8% 
36 – 40 17 28% 
41 – 45 7 12% 
46 – 50 7 12 
51 – 55 4 7% 
 
 Out of 60 patients studied, most of them were in the age group of       
36 – 40 years (n=17) and the least number in the age group of 51 – 55 years 
(n=4).   
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AGE DISTRIBUTION OF PATIENTS 
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TABLE 3 : SEX DISTRIBUTION OF PATIENTS 
 
Age Range Male Female Total 
18 – 25 5 7 12 
26 – 30 4 4 08 
31 – 35 4 1 05 
36 – 40 9 8 17 
41 – 45 3 4 07 
46 – 50 6 1 07 
51 – 55 1 3 04 
Total  32 28 60 
 
 Out of 60 patients studied, highest number (n=17) is in the age group 
of 36 – 40 of which 9 patients were male and 8 patients were female.   
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SEX DISTRIBUTION OF PATIENTS 
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TABLE 4 : SIGNIFICANCE BETWEEN AST LEVELS AND 
BLEEDING TENDENCIES 
 
 
Bleeding 
Total 
Present Absent 
AST 
category 
High 29 7 36 
Normal 0 24 24 
Total 29 31 60 
 
Chi square test was applied to test the significance between the AST 
levels and bleeding tendencies. There was a significant difference                  
(p = 0.000) found between the variations in the AST levels and the bleeding 
tendencies.  This implies that bleeding tendency depends upon the levels of 
AST. 
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SIGNIFICANCE BETWEEN AST LEVELS AND BLEEDING TENDENCIES 
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TABLE 5 : SIGNIFICANCE BETWEEN AST LEVELS AND 
SHOCK  
 
 
Shock 
Total 
Present Absent 
AST 
category 
High 13 23 36 
Normal 0 24 24 
Total 13 47 60 
 
Chi square test was applied to test the significance between the AST 
levels and shock. There was a significant difference (p = 0.001) found 
between the variations in the AST levels and shock.  This implies that shock 
depends upon the levels of AST. 
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SIGNIFICANCE BETWEEN AST LEVELS AND SHOCK  
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TABLE 6 : SIGNIFICANCE BETWEEN AST LEVELS AND 
HEPATOSPLENOMEGALY 
 
 
 
Hepatosplenomegaly 
Total 
Present Absent 
AST 
category 
High 6 30 36 
Normal 0 24 24 
Total 6 54 60 
 
 
 
Chi square test was applied to test the significance between the AST 
levels and Hepatosplenomegaly. There was a significant difference              
(p = 0.035) found between the variations in the AST levels and 
Hepatosplenomegaly.  This implies that hepatosplenomegaly depends upon 
the levels of AST. 
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SIGNIFICANCE BETWEEN AST LEVELS AND HEPATOSPLENOMEGALY 
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TABLE 7 : SIGNIFICANCE BETWEEN AST LEVELS AND ARDS 
 
 
 
ARDS 
Total 
Positive Negative 
AST 
category 
High 6 30 36 
Normal 0 24 24 
Total 6 54 60 
 
 
Chi square test was applied to test the significance between the AST 
levels and ARDS.  There was a significant difference (p = 0.035) found 
between the variations in the AST levels and ARDS.  This implies that 
ARDS depends upon the levels of AST. 
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SIGNIFICANCE BETWEEN AST LEVELS AND ARDS 
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TABLE 8 : SIGNIFICANCE BETWEEN AST LEVELS AND 
FREE FLUID IN ABDOMEN 
 
 
 
 
Free Fluid 
Total 
Present Absent 
AST 
category 
High 19 17 36 
Normal 0 24 24 
Total 19 41 60 
 
 
Chi square test was applied to test the significance between the AST 
levels and free fluid in abdomen. There was a significant difference              
(p = 0.000) found between the variations in the AST levels and free fluid in 
abdomen.  This implies that free fluid in abdomen depends upon the levels 
of AST. 
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SIGNIFICANCE BETWEEN AST LEVELS AND FREE FLUID IN ABDOMEN 
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TABLE 9 : SIGNIFICANCE BETWEEN AST LEVELS AND 
ALCOHOLIC CONSUMPTION 
 
 
 
Alcoholic 
Total 
Yes No 
AST 
category 
High 14 20 34 
Normal 4 18 22 
Total 18 38 56 
 
Chi square test was applied to test the significance between the AST 
levels and alcoholic consumption. There was no significant difference              
(p = 0.072) found between the variations in the AST levels and alcoholic 
consumption.  This implies that alcoholic consumption does not depends 
upon the levels of AST. 
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SIGNIFICANCE BETWEEN AST LEVELS AND ALCOHOLIC CONSUMPTION 
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TABLE 10 : CORRELATION BETWEEN AST LEVELS AND 
PLATELETS 
  
 
 Platelets 
/mm3 
AST 
Platelets 
/mm3 
Pearson 
Correlation 
1 -.306
*
 
Sig. (2-tailed) 
 .017 
N 
60 60 
AST 
Pearson 
Correlation 
-.306
*
 1 
Sig. (2-tailed) 
.017  
N 
60 60 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
 
 
 
There was a significant negative correlation between AST levels and 
platelet count (r = -0.306). This implies that increase in AST levels is 
associated with decrease in platelets. 
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CORRELATION BETWEEN AST LEVELS AND PLATELETS 
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TABLE 11 : CORRELATION BETWEEN AST LEVELS AND 
MEAN ARTERIAL PRESSURE 
 
 AST MABP 
AST 
Pearson 
Correlation 
1 -.593
**
 
Sig. (2-tailed)  .000 
N 60 60 
MABP 
Pearson 
Correlation 
-.593
**
 1 
Sig. (2-tailed) .000  
N 60 60 
**. Correlation is significant at the 0.01 level                
(2-tailed). 
 
 
There was a significant negative correlation between AST levels and 
mean arterial pressure count (r = -0.593). This implies that increase in AST 
levels is associated with decrease in platelets. 
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CORRELATION BETWEEN AST LEVELS AND MEAN ARTERIAL PRESSURE 
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TABLE 12 : CORRELATION BETWEEN ALT AND 
PLATELETS 
 
 
 
ALT 
Platelets 
/mm3 
ALT 
Pearson 
Correlation 
1 -.324
*
 
Sig. (2-tailed)  .011 
N 60 60 
Platelets 
/mm3 
Pearson 
Correlation 
-.324
*
 1 
Sig. (2-tailed) .011  
N 60 60 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
 
There was a significant correlation between ALT levels and Platelets 
count (r = -0.324). This implies that increase in ALT levels is associated 
with decrease in platelets. 
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CORRELATION BETWEEN ALT AND PLATELETS 
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TABLE 13 : CORRELATION BETWEEN ALT AND MEAN 
ARTERIAL BLOOD  PRESSURE 
 
 
 
 
ALT MABP 
ALT 
Pearson 
Correlation 
1 -.587
**
 
Sig. (2-tailed)  .000 
N 60 60 
MABP 
Pearson 
Correlation 
-.587
**
 1 
Sig. (2-tailed) .000  
N 60 60 
**. Correlation is significant at the 0.01 level (2-
tailed). 
 
 
 
There was a significant correlation between ALT levels and mean 
arterial blood pressure (r = -0.587). This implies that increase in ALT levels 
is associated with decrease in mean arterial blood pressure.  
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CORRELATION BETWEEN ALT AND MEAN ARTERIAL BLOOD  PRESSURE 
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TABLE 14 
SIGNIFANCE BETWEEN THROMBOCYTOPENIA AND 
BLEEDING TENDENCIES 
 
 
 
 
Thrombocytopenia 
Total 
Yes No 
Bleeding 
Present 27 2 29 
Absent 29 2 31 
Total 56 4 60 
 
Chi square test was applied to test the significance between the 
thrombocytopenia and bleeding tendencies. There was no significant 
difference (p = 0.945) found between the variations in the thrombocytopenia 
and the bleeding tendencies.  This implies that bleeding tendencies does not 
depends upon thrombocytopenia. 
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SIGNIFANCE BETWEEN THROMBOCYTOPENIA AND BLEEDING TENDENCIES 
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TABLE 15 : MEAN VALUE OF SERUM AMINOTRANSFERASES 
IN LIVER ENZYMES ELEVATED PATIENTS 
 
 
 
 
 
 
  
 
In our study,  of those patients with elevated liver enzymes, AST was 
found to be higher than ALT levels.   
 
 
Means Value 
AST High 259.45 
ALT High 199.75 
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MEAN VALUE OF SERUM AMINOTRANSFERASES IN LIVER ENZYMES ELEVATED PATIENTS 
 
RESULTS 
1. In this study, 60 patients of dengue IgM Elisa positive patients were 
studied. 
2. Out of 60 patients, 32 were male and 28 were female. 
3. Most of the patients were in the age group of 36 – 40 and none of 
them were below 18 years and above 55 years of age. 
4. All the patients had fever as a presenting complaint.  Most of them 
had myalgia at the time of presentation. 
5. Six patients had hepatomegaly with or without spleenomegaly 
clinically. 
6. Six patients presented with ARDS as a presenting feature.  19 patients 
had free fluid in USG abdomen.  Bleeding tendencies were seen in 29 
patients. 
7. In our study, alcohol intake does not influence the levels of liver 
enzymes significantly. 
8. Statistically, there was no significance between liver enzymes and age 
groups. 
9. Elevated liver enzymes were found in 36 patients overall.  Elevated 
liver enzymes were found in 29 patients with bleeding tendencies, 13 
patient with shock, 6 patients with ARDS, 6 patients with 
hepatosplenomegaly and 19 patients with ascites in USG abdomen.     
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10. Of the liver enzymes, AST levels were significantly higher than    
ALT levels. 
11. Thrombocytopenia was noted in 56 patients of which 27 had 
bleeding and 29 had no bleeding. 
12. There was a negative correlation between levels of liver enzymes 
and platelet count.   
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DISCUSSION 
 Currently dengue is causing major public health concern 
throughout the World particularly in South East Asian countries.  
Recently dengue outbreaks caused significant morbidity and mortality 
in certain parts of Tamil Nadu mainly in Chennai, Tirunelveli and 
Madurai. 
 Hepatic dysfunction in dengue are common.  It is due to either 
direct effect of virus on hepatocytes or due to reactive hepatitis.  
Hepatic involvement in dengue fever is in the form of elevated serum 
aminotransferase.  Those patients with elevated liver enzymes are more 
likely to have increased risk of bleeding tendencies, shock, ARDS, 
renal failure and acalculous cholectystitis.  In addition to decreased 
platelet count, hepatic dysfunction plays a significant role in bleeding.  
Hence, it is mandatory to evaluate serum aminotransferases in all 
patients with dengue fever. 
 It is found that, out of 60 patients, 36 patients had elevated liver 
enzymes and these patients had more complications like bleeding, 
shock, ARDS and hepatitis.  Among the liver enzymes, AST levels are 
higher compared to the ALT levels.   
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 Chen HC et al in 2004 found out that three tenth of patients with 
dengue had hepatic involvement.  Hepatic involvement is significantly 
higher in Asian populations from 31.92%.  They also found out that the 
rate of hepatic dysfunction in shock patients was somewhat higher than 
that of non shock patients. 
 Pancharoen et al found that mean values of AST and ALT were 
significantly increased in patients with DHF. 
 Kho CH et al reported that increased levels of AST and ALT are 
associated with severe bleeding manifestations in dengue patients. 
 In our study, out of 60 patients, 56 patients had 
thrombocytopenia.  Out of 56 patients with thrombocytopenia, 27 
patients were found to have bleeding tendencies and other 29 patients 
were found to have no bleeding, whereas out of 36 patients with 
elevated liver enzymes, 29 patients had bleeding tendencies.   
 Nguyen et al found that damaged liver function plays a 
significant role in bleeding in addition to thrombocytopenia. 
 Out of 60 patients, 13 patients were presented in shock.  In all 13 
patients liver enzymes were elevated with AST levels more than ALT 
levels.   
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 Arun Sedhain et al study reported that AST and ALT levels were 
increased in DHF patients than DF significantly.  They also found that 
AST levels were greater than ALT levels in contrast to viral hepatitis. 
 “Larreal Y et al reported jaundice in only two of 63 patients 
studied in their study known as hepatic alteration in dengue”. 
 Arun Sedhain et al found that USG abdomen findings includes 
hepatomegaly.  Gall bladder thickening and third space loss.  They 
were higher significantly in DHF as compared to DF patients.       
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LIMITATION OF STUDY 
1. Small sample size (60) 
2. We did not check for dengue virus sub types. 
3. Almost all the patients with dengue fever had thrombocytopenia.  
Thrombocytopenia was noticed in all patients with elevated liver 
enzymes.   
4. Duration of study is six months only.   
5. Antibody titres were not quantitated.   
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CONCLUSION 
 Hepatic involvement is common in dengue fever.  It is 
characterized by elevated liver enzymes, AST more than ALT levels.  
Elevated liver enzymes are associated with complications like 
bleeding, shock and organ impairment.  In addition to 
thrombocytopenia, hepatic involvement plays a significant role in 
bleeding.  Elevated live enzymes have got prognostic value in this 
study.  Hence, liver enzymes are mandatory in dengue fever to look for 
complications and it is of prognostic value.  Those patients with 
elevated liver enzymes should be monitored carefully than those 
patients with normal liver enzymes.    
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ABBREVIATIONS 
 DF   : Dengue Fever 
 DHF   : Dengue Haemorrhagic Fever 
 DSS   : Dengue Shock Syndrome 
 AST   : Aspartate Aminotransferase 
 ALT   : Alanine Aminotransferase 
 MABP  : Mean Arterial Blood Pressure 
 LFT   : Liver Function Test  
 PT   : Prothrombin time 
 APTT  : Activated Partial Thromboplastin Time 
 FF   : Free Fluid 
 ARDS  : Acute Respiratory Distress Syndrome 
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PROFORMA 
Name    :    IP No.  : 
Age/Sex   :    Patient ID No. : 
 
History 
□ Fever □ Bleeding tendencies 
□ Joint pain □ Oliguria 
□ Headache □ Alcoholism 
□ Giddiness □ Abdominal pain 
□ Others  
 
Clinical Examination 
□ Pallor □ Petechiae/purpura 
□ Icterus □ Bleeding gums 
□ Pedal edema □ Subconjunctival hemorrhage 
□ Hepatomegaly □ Splenomegaly 
 
Vitals 
Temperatur  Pulse  
Respiratory rate  Blood pressure  
 
INVESTIGATIONS 
RFT LFT 
Glucose           mg/dl Total bilirubin          mg/dl 
Urea          mg/dl Direct bilirubin          mg/dl 
Cratinine          mg/dl ALP          U/l 
Na
+
          mEq/l Total protein g/dl 
K
+ 
         mEq/l
 
Albumin g/dl 
USG abdomen Chest x-ray 
 
 
 
CBC Fever Workup 
TC       mm
3
 QBC for MP/Mf  
DC  MSAT for leptospirosis  
ESR mm/hour Blood culture  
Hemoglobin g/dl Widal test  
RBC count /mm3 Anti-HAV  
IgM Elisa for Dengue HBsAg  
Anti-HCV  
100 
 
 
 
Parameter Day 1 Day 3 Day 7 
AST (U/l)    
ALT (U/l)    
Platelet count (/mm
3
)    
Hematocrit (%)    
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1 Ganesan 35 M 10 - Occasional - - - - - NAD NAD + ve 
2 Purushothaman 40 M 12 + + Joint pain + - + - NAD NAD + ve 
4 Leya 38 F 8 - - + + - - - ARDS FF+ + ve 
4 Rajalakshmi 19 F 7 - - + - - - - - NAD + ve 
5 Karpagam 28 F 8 + - + + - + - - - + ve 
6 Mariammal 36 F 10 - - + - - - - - - + ve 
7 Prabhakaran 27 M 12 + + + - - + + - FF+ + ve 
8 Balaji 31 M 13 + + + - - + - - - + ve 
9 Kannan 46 M 7 + + - - - - - - - + ve 
10 Murali 20 M 8 - - - - - - - - - + ve 
11 Vinoth 19 M 9 - - + - - - - - - + ve 
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12 Kumar 32 M 13 + + - - - - - - FF+ + ve 
13 Parvathy 19 F 12 + - + - - + - - - + ve 
14 Shanmugapriya 20 F 10 - - - - - - - - - + ve 
15 Shankari 39 F 210 - - + - - + - NAD NAD + ve 
16 Rajesh 29 M 6 - - + - - - - ARDS FF + ve 
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1 90 130/80 14 99 38 0.9 0.9 90000 28 25 84 120/80 15 98.4 36 0.7 0.8 97000 26 22 
2 105 90/60 15 101 44 1.0 0.8 78000 380 320 96 100/70 14 99.6 40 0.9 0.9 89000 300 260 
4 120 90/60 36 102 46 1.0 1.1 58000 550 380 100 100/60 18 99 30 0.9 0.8 65000 390 170 
4 116 80/? 16 98.8 40 0.6 0.8 88000 250 140 98 110/70 15 98.6 28 0.7 0.7 94000 280 120 
5 90 110/70 15 101 28 0.7 0.6 65000 210 160 84 110/80 14 99.2 30 0.8 0.8 80000 170 100 
6 84 120/70 14 98.8 24 0.6 0.6 110000 20 22 79 110/70 13 98.4 26 0.7 0.7 140000 22 18 
7 98 110/70 13 102 36 0.9 0.7 55000 360 280 88 120/80 14 99.7 30 0.8 0.9 78000 270 175 
8 96 110/80 13 100 30 0.6 0.9 60000 290 185 82 120/70 13 98.9 32 0.7 0.8 85000 150 80 
9 94 130/70 13 102 28 0.5 0.8 120000 185 100 88 120/80 16 100 30 0.8 0.9 130000 145 65 
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10 88 110/70 12 99.2 24 0.7 0.6 65000 29 22 80 110/80 13 98.7 32 0.6 0.7 78600 26 24 
11 80 100/80 13 99.7 26 0.8 0.8 55000 23 20 76 120/70 12 99.4 30 0.9 0.9 70000 20 18 
12 94 100/70 14 99.5 28 0.9 0.9 91000 110 78 89 110/80 13 99.2 26 0.9 0.7 96000 79 48 
13 98 110/80 13 102 38 0.8 1.0 36000 65 43 96 100/70 12 101 29 1.0 0.9 40000 55 41 
14 90 130/70 12 98.6 30 0.7 0.7 91000 18 15 86 110/80 12 98.4 24 0.6 0.7 99000 20 21 
15 110 80/? 17 99.9 39 1.0 0.9 61000 380 270 99 100/70 15 99 32 0.9 0.7 78000 306 196 
16 104 90/60 27 99.7 41 1.1 1.0 70000 630 495 90 100/80 17 99.1 34 0.9 0.9 80000 410 315 
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1 80 120/70 13 98.3 28 0.6 0.8 110000 23 25 
2 86 130/80 12 98.5 30 0.7 0.7 140000 160 100 
4 82 130/90 12 98.2 32 0.8 0.7 99000 150 86 
4 86 120/80 14 98.3 28 0.7 0.6 130000 120 68 
5 80 110/70 13 98.4 26 0.6 0.7 96000 110 48 
6 78 120/70 13 98.2 29 0.8 0.7 165000 20 16 
7 80 120/70 15 98.8 22 0.6 0.6 98000 165 95 
8 78 110/80 14 98.3 26 0.5 0.5 96000 95 65 
9 76 120/70 13 98.7 22 0.9 0.7 148000 90 46 
10 79 110/70 14 98.6 28 0.7 0.7 91000 26 20 
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11 75 120/70 13 98.5 26 0.6 0.8 96000 18 16 
12 76 120/80 12 98.7 29 0.7 0.7 115000 57 39 
13 90 110/70 12 99.9 32 0.9 0.7 59000 45 32 
14 84 120/80 11 98.6 30 0.8 0.8 145000 19 16 
15 72 120/70 13 98.7 30 0.6 0.5 105000 190 110 
16 80 120/80 12 98.8 32 0.9 0.7 99000 170 118 
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17 Deepa 20 F 8 - - + - - - - - - + ve 
18 Puhalenthi 37 M 12 + - + + - + - - - + ve 
19 Selvam 30 M 10 + - + + - + - - FF + ve 
20 Venkatesh 23 M 8 -   - - - - - - - + ve 
21 Muniyammal 55 F 7 + - + + - + - - - + ve 
22 Muthupandiyan 49 M 13 -   - - - - - ARDS FF+ + ve 
23 Rajasekaran 39 M 11 -   + + - + - - - + ve 
24 Aaseela Begum 23 F 10 - - + - - - - - - + ve 
25 Ismayil 40 M 11 -   + - - - - - - + ve 
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26 Kandhammar 51 F 12 + - - + - + - - FF+ + ve 
27 Suseela 43 F 6 - - + - - - - - - + ve 
28 Muthamizh 32 F 8 + - + + - + - - - + ve 
29 Saranya 20 F 9 - - + - - - - - - + ve 
30 Shanmugam 46 M 13 + - - + - + + - FF + ve 
31 Ashok 45 M 12 - + + - - + + NAD NAD + ve 
32 Mani 31 M 10 + + + - - + - NAD FF+ + ve 
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17 90 110/70 15 98.9 30 0.9 0.9 69000 20 22 86 110/80 14 98.6 28 0.7 0.8 89000 20 23 
18 99 90/60 17 99.5 24 0.8 0.8 48000 410 298 90 100/70 15 98.9 24 0.9 0.9 59000 298 179 
19 106 90/? 16 99.9 28 0.9 0.9 88000 295 205 98 100/80 14 99 26 0.8 0.8 98000 150 115 
20 90 110/70 15 100 26 0.6 0.6 65000 18 13 89 110/70 13 98.7 25 0.7 0.9 70000 19 17 
21 118 80/? 14 100 30 0.7 0.7 49000 310 240 95 100/70 14 99.2 29 0.6 0.7 58800 295 180 
22 110 100/70 28 102 32 0.6 0.5 71000 215 145 98 100/80 20 99.1 30 0.7 0.5 89000 140 97 
23 104 90/70 16 103 34 0.5 0.6 62000 189 117 91 110/70 13 99 31 0.8 0.7 79000 110 81 
24 90 110/80 17 99.8 30 0.8 0.8 79000 12 10 79 110/80 12 98.9 26 0.7 0.9 87000 18 17 
25 88 120/80 15 101 21 0.9 0.7 61000 18 19 86 110/80 11 98.7 27 0.8 0.7 82000 17 15 
110 
 
26 101 90/70 14 102 29 0.7 0.8 70000 210 165 95 110/70 12 98.9 26 0.9 0.9 89000 155 99 
27 90 120/80 13 103 36 0.6 0.9 110000 15 14 79 120/80 11 98.7 21 0.7 0.8 125000 16 17 
28 99 110/80 19 101 35 0.5 0.9 91000 206 179 89 110/70 12 99.2 37 0.9 1.0 98000 149 101 
29 90 110/70 15 100 46 1.5 0.6 86000 175 105 81 110/80 13 98.7 41 0.9 0.7 104000 105 73 
30 95 120/70 17 99.9 32 0.6 0.9 48000 79 61 80 130/70 12 99 31 0.7 0.8 67000 61 43 
31 102 110/70 15 99.9 30 0.9 0.6 59000 352 298 90 120/80 15 98.9 30 0.8 0.7 71000 278 196 
32 108 90/60 18 101 32 1.0 1.0 70000 296 185 98 100/70 14 99.2 28 0.9 0.8 85000 147 87 
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17 88 120/70 13 98.7 30 0.7 0.9 110000 19 24 
18 84 110/80 14 98.6 28 0.9 0.8 90000 117 81 
19 88 110/70 14 98.7 31 0.7 0.9 110000 78 61 
20 89 110/80 13 99.7 28 0.7 0.8 88000 17 16 
21 81 120/70 12 99 31 0.6 0.7 91000 105 87 
22 85 120/80 13 98.7 28 0.7 0.8 115000 65 41 
23 79 130/80 12 98.8 26 0.9 0.8 97600 71 50 
24 75 110/70 11 98.6 21 0.7 0.6 126000 21 20 
25 80 120/70 13 98.5 20 0.8 0.8 110000 15 16 
26 88 120/80 12 98.6 25 0.6 0.9 99300 88 49 
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27 72 110/80 13 98.4 21 0.7 0.8 165000 17 16 
28 74 100/70 12 98.3 26 0.8 0.9 118000 81 62 
29 77 130/70 13 98.6 27 0.7 0.6 115000 80 52 
30 71 110/80 12 98.5 28 0.6 0.5 92000 48 30 
31 89 120/70 14 98.7 31 0.6 0.7 95000 145 110 
32 86 130/70 13 98.6 30 0.9 0.8 97000 91 59 
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33 Divya 26 F 8 - - - - - - - NAD NAD + ve 
34 Shanthi 46 F 6 - - + - - - - - - + ve 
35 Geetha 29 F 7 - - + - - + - - FF+ + ve 
36 Bharath 26 M 9 - + - - - - - - - + ve 
37 Manoj 22 M 10 - - - - - - - - - + ve 
38 Henith Raj 26 M 12 - - - - - + - - - + ve 
39 Vivek 39 M 10 + - + - - + - - FF+ + ve 
40 Selvi 42 F 9 - - + + - + + - FF+ + ve 
41 Aarthi 36 F 11 - - + - - - - - - + ve 
42 Prabha 21 F 7 - - - - - - - - - + ve 
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43 David 39 M 11 + + + - - + - - FF+ + ve 
44 Siva 46 M 10 + + + - - + - ARDS FF+ + ve 
45 Hema 36 F 12 - - - - - - - - - + ve 
46 Preethi 38 F 9 - - + - - + - - - + ve 
47 Kalpana 43 F 10 - - + - - - - - - + ve 
48 Basker 50 M 12 + + + - - + - - FF+ + ve 
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33 91 110/70 13 99 28 0.8 0.9 85000 18 15 82 110/80 13 98.9 30 0.8 0.9 96000 19 17 
34 87 120/70 12 98.7 30 0.9 0.8 66000 15 14 80 120/70 12 98.4 31 0.7 0.8 79000 21 18 
35 105 90/70 19 99.8 36 0.9 0.6 59000 210 155 94 100/80 13 98.9 32 0.7 0.8 75000 159 106 
36 95 110/80 18 99.9 30 0.8 0.5 61000 16 14 89 110/70 17 99 28 0.6 0.7 77000 19 17 
37 89 120/70 13 99.7 26 0.7 0.6 85000 19 13 80 110/80 13 98.9 24 0.7 0.9 98000 16 15 
38 98 90/70 12 99.9 28 1.0 0.9 88000 190 119 90 110/70 12 99.7 26 0.9 0.8 99600 115 84 
39 94 100/70 13 99 26 0.9 0.8 91000 85 69 88 110/70 12 98.9 28 0.9 0.7 101000 59 49 
40 99 90/70 14 99.8 38 1.0 0.9 78000 256 215 92 100/80 13 99.2 36 0.9 0.9 87900 179 148 
41 90 110/70 13 98.7 36 1.0 0.9 65000 19 17 84 110/70 14 98.6 30 0.8 0.7 78000 19 18 
42 88 120/70 12 98.8 30 0.8 0.7 78000 25 26 82 110/80 13 98.5 30 0.7 0.7 89000 28 26 
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43 116 80/? 19 102 38 1.0 0.9 38000 325 255 98 100/70 18 99 32 0.9 0.8 60000 215 156 
44 122 90/70 36 101 36 0.9 0.8 32000 290 276 99 100/80 19 99.4 30 0.8 0.7 55000 204 186 
45 78 130/80 15 102 30 0.8 0.8 78000 24 26 86 110/70 18 99.5 28 0.9 0.9 90000 22 27 
46 95 120/70 18 98.7 31 0.7 0.5 101000 125 105 89 120/80 17 98.6 26 0.7 0.8 110000 79 63 
47 88 120/70 16 98.9 28 0.9 0.7 91000 17 16 78 110/80 15 98.7 28 0.7 0.7 110000 25 26 
48 106 90/70 15 98.8 32 0.8 0.9 71000 125 99 98 100/70 14 98.6 30 0.6 0.8 90000 98 79 
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33 76 110/80 12 98.5 28 0.7 0.7 120000 19 18 
34 74 130/70 11 98.7 26 0.6 0.9 110000 18 16 
35 79 110/80 12 98.6 30 0.7 0.9 98000 93 79 
36 87 110/80 13 98.7 30 0.6 0.7 106000 19 17 
37 78 110/70 12 98.6 28 0.7 0.6 110000 16 15 
38 76 120/70 13 98.8 26 0.8 0.8 115000 72 59 
39 79 110/80 12 98.7 27 0.8 0.8 115000 48 39 
40 80 110/80 13 98.5 26 0.7 0.8 97900 106 72 
41 76 110/80 12 98.4 30 0.7 0.8 102000 17 16 
42 80 120/70 13 98.5 30 0.8 0.8 110000 25 28 
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43 86 110/80 12 98.7 28 0.7 0.7 98000 116 89 
44 84 110/70 13 98.9 24 0.9 0.8 91000 105 91 
45 86 110/80 12 98.6 26 0.7 0.7 110000 25 24 
46 88 120/70 13 98.7 25 0.8 0.8 135000 55 49 
47 76 120/70 15 98.5 28 0.6 0.7 125000 24 23 
48 88 120/80 14 98.4 26 0.7 0.7 110000 71 52 
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49 Sivakumar 38 M 9 - + - - - - - - - + ve 
50 Ilanchezhian 44 M 6 - + - - - + - - FF+ + ve 
51 Pushpavalli 55 F 11 - - + - - - - - - + ve 
52 Ponnammal 43 F 10 - - + - - + + ARDS FF+ + ve 
53 Vasantha 38 F 8 + - + - - - - - - + ve 
54 Nagammal 39 F 7 - - - - - - - - - + ve 
55 Suresh 40 M 6 + + + - - + + - FF+ + ve 
56 Gopal 20 M 12 - + + - - - - ARDS - + ve 
57 Raja 45 M 13 - - + - - - - - - + ve 
58 Radhakrishnan 50 M 10 - + + - - - - - FF+ + ve 
59 Raghunathan 53 M 9 - + - - - - - - - + ve 
60 Banu 36 F 8 - - + - - - - - - + ve 
120 
 
S
l
.
N
o
.
 
Parameters Parameters 
Day 1 Day 3 
P
R
/
m
t
 
B
P
 
(
m
m
H
g
)
 
R
R
/
m
t
 
T
e
m
p
.
°
F
 
U
r
e
a
 
 
(
m
g
/
d
L
)
 
C
r
e
a
t
i
n
i
n
e
 
m
g
/
d
L
 
T
B
,
 
D
B
 
m
g
/
d
L
 
P
l
a
t
e
l
e
t
s
 
/
m
m
3
 
A
S
T
 
(
I
U
/
L
)
 
A
L
T
 
(
I
U
/
L
)
 
P
R
/
m
t
 
B
P
 
(
m
m
H
g
)
 
R
R
/
m
t
 
T
e
m
p
.
°
F
 
U
r
e
a
 
 
(
m
g
/
d
L
)
 
C
r
e
a
t
i
n
i
n
e
 
m
g
/
d
L
 
T
B
,
 
D
B
 
m
g
/
d
L
 
P
l
a
t
e
l
e
t
s
 
/
m
m
3
 
A
S
T
 
(
I
U
/
L
)
 
A
L
T
 
(
I
U
/
L
)
 
49 89 120/80 14 99.4 30 0.7 0.6 90000 19 20 88 110/80 13 98.8 28 0.7 0.7 97000 22 24 
50 104 80/? 19 99.9 28 1.0 0.5 56000 308 295 99 100/70 14 99 30 0.8 0.8 68000 199 119 
51 92 120/70 15 98.9 26 0.7 0.7 80000 21 24 88 110/80 15 98.7 26 0.7 0.9 88800 24 27 
52 106 100/70 38 99 28 1.0 1.0 86000 306 290 92 110/70 18 98.5 24 0.8 0.9 98000 221 145 
53 105 90/60 18 98.9 24 0.6 0.6 70000 159 119 98 100/70 15 98.7 26 0.9 0.7 86000 101 69 
54 88 130/90 15 98.6 30 0.4 0.5 58000 29 27 86 130/80 14 98.5 30 0.6 0.5 72000 27 26 
55 118 80/? 19 99.9 32 0.9 0.8 80000 389 365 102 100/70 16 99 30 0.9 0.8 90000 257 215 
56 102 100/70 32 99.8 36 0.8 0.7 61000 215 185 91 100/70 25 98.9 31 0.8 0.6 73000 145 116 
57 88 130/90 15 101 24 0.5 0.5 79000 18 15 89 120/80 13 99.6 26 0.7 0.5 86000 21 23 
58 106 90/70 13 99.6 29 0.9 0.7 65000 210 195 99 100/70 15 99.2 28 0.8 0.6 79000 136 105 
59 88 130/70 12 99.8 30 0.8 0.7 78000 28 29 88 110/80 13 99.2 30 0.7 0.9 93000 30 33 
60 84 110/70 13 98.7 24 0.7 0.5 91000 20 18 86 120/70 14 98.7 24 0.6 0.8 175000 20 17 
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49 86 130/70 13 98.6 27 0.6 0.6 125000 22 24 
50 86 110/70 13 98.8 28 0.7 0.7 99000 96 78 
51 84 120/80 12 98.4 26 0.8 0.8 110000 20 22 
52 86 120/70 13 98.6 29 0.9 0.9 108000 98 67 
53 84 120/80 12 98.4 39 0.8 0.8 99000 79 43 
54 81 130/80 13 98.4 30 0.6 0.6 103000 22 19 
55 89 110/70 12 98.7 28 0.7 0.7 106000 141 106 
56 89 110/80 14 98.7 26 0.6 0.6 96000 79 61 
57 86 120/80 13 98.9 24 0.7 0.7 105000 25 27 
58 88 120/70 13 98.7 26 0.8 0.8 99000 86 73 
59 86 120/70 12 98.9 28 0.7 0.7 115000 26 27 
60 82 120/80 13 98.4 24 0.8 0.8 125000 28 26 
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